Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US District Court for the Eastern District of Virginia has ruled in favor of Pfizer in a patent infringement case related to Viagra against Teva Pharmaceuticals.
Subscribe to our email newsletter
Viagra, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
According to the court’s decision, Teva will not be able to receive approval for generic Viagra till October 2019.
Pfizer executive vice president and general counsel Amy Schulman said protecting the intellectual property rights of their core is critical, and the court decision acknowledges Teva’s clear violation of their patent rights.